Cat. No.: HY-113416

Dehydroepiandrosterone sulfate

(Synonyms: DHEA sulfate; Prasterone sulfate)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 651-48-9
Formula: C₁₉H₂₈O₅S
Molecular Weight:368.49

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dehydroepiandrosterone sulfate Chemical Structure

CAS No.: 651-48-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

Sigma 1 Receptor

PPARα

All Sigma Receptor Isoforms :

All iGluR Isoforms :

All PPAR Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	127 μM Compound: 50	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
Sf9	IC₅₀	3 μM Compound: Dehydroepiandrosterone-3-sulfate	TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing Sf9 cells TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing Sf9 cells	[PMID: 14643890]

In Vitro

Dehydroepiandrosterone sulfate (0.1 nM-10 μM; 2-24 h) increases neuronal survival in embryonic rat cortical cell hypoxia assay, with significant effects at 10 μM^[1].
Dehydroepiandrosterone sulfate (0.1-10 μM) protects neurons in rat cerebellar granule cell oxygen-glucose deprivation assay in a dose-dependent manner, with almost complete protection at 10 μM^[1].
Dehydroepiandrosterone sulfate (DHEAS) (1 μM-1 mM; 48 h) inhibits TNF-α-induced VCAM-1, IL-8, and ICAM-1 expression in human aortic endothelial cell inflammation assay, and inhibits NF-κB activity via activation of PPARα^[5].
Dehydroepiandrosterone sulfate (DHEAS) (10-7-10-5 M; 96 h) inhibits LIF-induced proliferation of juvenile bovine chromaffin cells and enhances EGF-induced proliferation of adult bovine chromaffin cells in a proliferation assay^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human aortic endothelial cells (HAECs)
Concentration:

0.1 μM-1 mM
Incubation Time:

48 hours
Result:

Had no significant effect on cell viability, as over 95% of cells remained viable across all concentrations tested, comparable to vehicle control.

RT-PCR^[5]

Cell Line:

Human aortic endothelial cells (HAECs)
Concentration:

1 mM
Incubation Time:

48 hours (pretreatment) + 4 hours (TNF-α stimulation)
Result:

Significantly reduced TNF-α-induced IL-8 and ICAM-1 mRNA expression by 5-fold and 2-fold, respectively, compared to TNF-α alone.

Western Blot Analysis^[5]

Cell Line:

Human aortic endothelial cells (HAECs)
Concentration:

1-1000 μM
Incubation Time:

48 hours
Result:

Increased IκB-α protein levels in a dose-dependent manner, with maximal induction at 1000 μM, correlating with NF-κB inhibition.

Cell Proliferation Assay^[6]

Cell Line:

Juvenile/adult bovine chromaffin cells
Concentration:

10^-7-10^-5 M
Incubation Time:

96 hours
Result:

Did not affect basal proliferation but inhibited LIF-induced proliferation by 30% at 10^-5 M.
In adult cells, enhanced EGF-induced proliferation by 25% at 10^-5 M, without effect at lower concentrations.

In Vivo

Dehydroepiandrosterone sulfate (DHEAS) (1 mg/kg; intravenous injection; single dose) reduces the threshold shift of compound action potentials and the amplitude of distortion product otoacoustic emissions in the noise-induced cochlear injury model of albino guinea pigs, and has a protective effect on the cochlea^[7].
Dehydroepiandrosterone sulfate (DHEAS) (converted from 2 mg/kg Dehydroepiandrosterone intraperitoneally; once daily; 13 days) can shorten the immobility time in the forced swim test in the male FSL rat model of depression, but when used in combination with electroconvulsive shock (ECS), it offsets the antidepressant effect of ECS^[8].
Dehydroepiandrosterone sulfate (DHEAS) (10 mg/kg; subcutaneous injection; once daily; 4 weeks) enhances the seizure sensitivity of Laka mice in the pentylenetetrazol-induced seizure model, as shown by a decrease in the half effective dose of seizure (ED₅₀ from 67.6 mg/kg to 48.6 mg/kg) and a shortens seizure latency, an effect that is reversed by Progesterone (HY-N0437) or Dizocilpine (HY-15084B)^[9].
Chronic treatment with Dehydroepiandrosterone sulfate for 4 weeks significantly reduces the body weight of mice in the pentylenetetrazol-induced seizure model^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Albino Guinea Pig Noise-Induced Cochlear Injury Model (250-350 g): 2 kHz pure tone (120-125 dB SPL for 10 min) induced cochlear injury^[7]
Dosage:

1 mg/kg Dehydroepiandrosterone sulfate
Administration:

Intravenous injection, single dose immediately before acoustic overexposure
Result:

Significantly improved cochlear function 1 week after acoustic exposure, reducing CAP threshold shifts and increasing DPOAE amplitude compared to control groups.
The protective effect was observed at 1 mg/kg but not at 0.1 mg/kg, with no significant effect immediately after exposure.

Animal Model:

Flinder Sensitive Line (FSL) Rat Model of Depression (male, 200-220 g, 6-8 weeks old): forced swim test (FST) assay^[8]
Dosage:

2 mg/kg Dehydroepiandrosterone (converted to Dehydroepiandrosterone sulfate)
Administration:

Intraperitoneal injection, daily for 13 days
Result:

Chronic Dehydroepiandrosterone administration (converted to Dehydroepiandrosterone sulfate) alone reduced immobility time in FST, mimicking antidepressant effects.
Combined treatment with electroconvulsive shock (ECS) abolished this effect, with immobility time significantly increased compared to DHEA or ECS alone, indicating DHEAS may antagonize ECS efficacy.

Animal Model:

Mouse Pentylenetetrazol-Induced Seizure Model (20-25 g): Pentylenetetrazol-induced tonic convulsions^[9]
Dosage:

10 mg/kg Dehydroepiandrosterone sulfate (dissolved in 0.1% Tween 80 saline)
Administration:

Subcutaneous injection, daily for 4 weeks
Result:

Chronic treatment shifted pentylenetetrazol dose-response curves leftward, reducing ED₅₀ for convulsions and shortening latency to seizure onset, indicating enhanced seizure sensitivity.
This proconvulsant effect was prevented by co-treatment with progesterone or dizocilpine, linking it to GABA_A receptor antagonism and NMDA receptor activation.

Chemical Information

CAS No. 651-48-9
Appearance Solid
Molecular Weight 368.49
Formula C₁₉H₂₈O₅S
Color White to off-white
SMILES

C[C@@]12[C@]3([H])[C@](CC=C1C[C@@H](OS(=O)(O)=O)CC2)([H])[C@@]4([H])[C@@](C)(C(CC4)=O)CC3
Synonyms

DHEA sulfate; Prasterone sulfate
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All

Sort by:

Journal Impact Factor

Cell Metab

Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. [Abstract]

2024 Nov 5;36(11):2402-2418.e10. PMID: 39389061
Nat Chem Biol

Structures of the ADGRG2-Gs complex in apo and ligand-bound forms. [Abstract]

2022 Nov;18(11):1196-1203. PMID: 35982227
Eur J Pharmacol

18β-Glycyrrhetinic acid synergizes with enzalutamide to counteract castration-resistant prostate cancer by inhibiting OATP2B1 uptake of dehydroepiandrosterone sulfate. [Abstract]

2024 Sep 12:176995. PMID: 39277096
Toxicol Appl Pharmacol

Icariin promotes mouse Leydig cell testosterone synthesis via the Esr1/Src/Akt/Creb/Sf-1 pathway. [Abstract]

2022 Apr 15:441:115969. PMID: 35259346
Research Square Print

2022 May.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (271.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7138 mL

13.5689 mL

27.1378 mL

5 mM

0.5428 mL

2.7138 mL

5.4276 mL

10 mM

0.2714 mL

1.3569 mL

2.7138 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Baulieu EE, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4279-84. [Content Brief]

[2]. Maninger N, et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009 Jan;30(1):65-91. [Content Brief]

[3]. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):377-85. [Content Brief]

[4]. Barrett-Connor E, et al. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986 Dec 11;315(24):1519-24. [Content Brief]

[5]. Altman R, et al. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. 2008 Feb-Mar;48(2-3):76-84. [Content Brief]

[6]. Sicard F, et al. Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate. Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):2007-12. [Content Brief]

[7]. Tabuchi K, et al. Dehydroepiandrosterone sulfate reduces acoustic injury of the guinea-pig cochlea. J Pharmacol Sci. 2005 Oct;99(2):191-4. [Content Brief]

[8]. Maayan R, et al. The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. Eur Neuropsychopharmacol. 2005 May;15(3):253-62. [Content Brief]

[9]. Reddy DS, et al. Proconvulsant effects of neurosteroids pregnenolone sulfate and dehydroepiandrosterone sulfate in mice. Eur J Pharmacol. 1998 Mar 12;345(1):55-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7138 mL	13.5689 mL	27.1378 mL	67.8444 mL
	5 mM	0.5428 mL	2.7138 mL	5.4276 mL	13.5689 mL
	10 mM	0.2714 mL	1.3569 mL	2.7138 mL	6.7844 mL
	15 mM	0.1809 mL	0.9046 mL	1.8092 mL	4.5230 mL
	20 mM	0.1357 mL	0.6784 mL	1.3569 mL	3.3922 mL
	25 mM	0.1086 mL	0.5428 mL	1.0855 mL	2.7138 mL
	30 mM	0.0905 mL	0.4523 mL	0.9046 mL	2.2615 mL
	40 mM	0.0678 mL	0.3392 mL	0.6784 mL	1.6961 mL
	50 mM	0.0543 mL	0.2714 mL	0.5428 mL	1.3569 mL
	60 mM	0.0452 mL	0.2261 mL	0.4523 mL	1.1307 mL
	80 mM	0.0339 mL	0.1696 mL	0.3392 mL	0.8481 mL
	100 mM	0.0271 mL	0.1357 mL	0.2714 mL	0.6784 mL

Keywords

Dehydroepiandrosterone sulfate

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dehydroepiandrosterone sulfate

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

GABA Receptor Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Animal-Sourced Natural Product Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lipid Metabolite Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Dehydroepiandrosterone sulfate

All Sigma Receptor Isoforms

All iGluR Isoforms

All PPAR Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References